FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF

1 - 31 . (canceled)

32 . A method of treating a disease, disorder, or condition in a subject, the method comprising administering to the subject a compound of general formula (IN), or a pharmaceutically acceptable salt thereof:

wherein:

Y 5 is an O atom or a S atom;

Y 4 and Y 6 are identical or different and are each independently selected from the group consisting of an O atom, a S atom, and —(CR m R n ) k —, provided that Y 4 and Y 6 are not both heteroatoms;

R m and R n are identical or different and are each independently selected from the group consisting of a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

k is 1 or 2;

ring B is phenyl or 5- or 6-membered heteroaryl;

M is a N atom or a C atom;

is a single bond or double bond; when M is a N atom, is a single bond, and when M is a C atom, is a single bond or double bond;

ring A is aryl or heteroaryl;

each R 1 is independently selected from the group consisting of a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

R 2 is selected from the group consisting of a hydrogen atom, alkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

each R 3 is independently selected from the group consisting of a hydrogen atom, halogen, alkyl, oxo, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

each R 4 is independently selected from the group consisting of a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

R 5 is selected from the group consisting of a hydrogen atom, halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, nitro, hydroxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

each R 6 is independently selected from the group consisting of a hydrogen atom, halogen, alkyl, alkoxy, cyano, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

n is 0, 1, 2, or 3;

m is 0, 1, 2, 3, or 4;

p is 0, 1, 2, or 3; and

q is 0, 1, 2, 3, or 4, and

wherein the disease, disorder, or condition is selected from type I diabetes, type II diabetes, malnutrition-related diabetes, diabetes complications, obesity, hyperglycemia, glucose intolerance, cardiovascular diseases, hyperlipidemia, cerebral infarction, strokes, nonalcoholic steatohepatitis (NASH), Parkinson's disease, dementia, insulin resistance, and hepatic insulin resistance.

33 . The method of claim 32 , wherein the compound 1s represented by general formula (INa), or a pharmaceutically acceptable salt thereof:

34 . The method of claim 32 , wherein ring B is selected from the group consisting of phenyl, pyridinyl, and thienyl.

35 . The method of claim 32 , wherein the compound 1s represented by general formula (IIG), or a pharmaceutically acceptable salt thereof:

wherein:

G is a C atom or a N atom.

36 . The method of claim 32 , wherein the compound 1s represented by general formula (IIGa), or a pharmaceutically acceptable salt thereof:

wherein:

G is a C atom or a N atom.

37 . The method of claim 32 , wherein the compound 1s represented by general formula (IIN), or a pharmaceutically acceptable salt thereof:

38 . The method of claim 32 , wherein Y 4 and Y 5 are each O atoms, and Y 6 is —(CR m R n ) k —.

39 . The method of claim 38 , wherein:

R m and R n are identical or different and are each independently selected from the group consisting of a hydrogen atom, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, hydroxy C 1-6 alkyl, cyano, amino, nitro, hydroxy, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl.

40 . The method of claim 32 , wherein the compound 1s represented by general formula (IIIN-1) or general formula (IIIN-2), or a pharmaceutically acceptable salt thereof:

41 . The method of claim 32 , wherein

is selected from the group consisting of

42 . The method of claim 32 , wherein

43 . The method of claim 32 , wherein ring A is 6- to 10-membered aryl or 5- to 10-membered heteroaryl.

44 . The method of claim 32 , wherein ring A is selected from the group consisting of phenyl, 5- or 6-membered heteroaryl, and

wherein ring C′ is 5- or 6-membered heteroaryl.

45 . The method of claim 32 , wherein

is selected from the group consisting of

46 . The method of claim 45 , wherein

47 . The method of claim 32 , wherein each R 1 is independently selected from the group consisting of a hydrogen atom, halogen, and C 1-6 alkyl.

48 . The method of claim 32 , wherein R 2 is C 1-6 alkyl, and is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, C 1-6 alkoxy, 3- to 6-membered cycloalkyl, and 3- to 6-membered heterocyclyl.

49 . The method of claim 32 , wherein each R 3 is independently selected from the group consisting of a hydrogen atom, halogen, oxo, and C 1-6 alkyl.

50 . The method of claim 32 , wherein each R 4 is independently selected from the group consisting of a hydrogen atom, halogen, and C 1-6 alkyl.

51 . The method of claim 32 , wherein R 5 is a hydrogen atom or C 1-6 alkyl.

52 . The method of claim 32 , wherein each R 6 is independently selected from the group consisting of a hydrogen atom, halogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, and C 1-6 haloalkyl.

53 . The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt thereof, is selected from:

54 . The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt thereof, is:

55 . The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt thereof, is:

56 . The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt thereof, is:

57 . The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt thereof, is:

58 . The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt thereof, is:

59 . The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt thereof, is:

60 . The method of claim 32 , wherein the disease, disorder, or condition is obesity.

61 . The method of claim 32 , wherein the disease, disorder, or condition is type II diabetes.

62 . The method of claim 32 , wherein the disease, disorder, or condition is diabetic complications.

63 . The method of claim 62 , wherein the diabetic complications are diabetic retinopathy, diabetic nephropathy, or diabetic neuropathy.